EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer

Audrey Beaufils iD, Julien De Martino iD, Xiaofeng Jiang, Théau Blanchard iD, Nicolas Fraunhoffer, Diana Mendes iD, Camille Pignolet iD, Taib Bourega iD, Asier Rabasco Meneghetti iD, Srividhya Sainath iD, Miguel Albuquerque iD, Nathalie Colnot iD und 21 weitere

Journal of Clinical Oncology · 2026

DOI: 10.1200/jco-26-00327 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Audrey Beaufils und 32 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche sur l'Inflammation (CRI), Université Paris Cité, INSERM, U1149, CNRS, ERL 8252, Paris, France. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Pancreatic Ductal, Deep Learning. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The choice of adjuvant chemotherapy in pancreatic ductal adenocarcinoma (PDAC) is mainly guided by patients' general condition. We hypothesized that tumor morphology may predict differential treatment benefit and tested whether deep learning applied to histology images could derive a biomarker of relative benefit from gemcitabine (GEM) versus modified FOLFIRINOX (mFOLFIRINOX) in resected PDAC. PATIENTS AND METHODS Standard whole-slide images from a retrospective multicentric series of 231 patients who underwent curative-intent pancreatectomy and received adjuvant mFOLFIRINOX (n = 54) or GEM (n = 177) were used to train regimen-specific histology models on disease-free survival (DFS), which were then combined into PANCprAId, a biomarker estimating personalized relative benefit from adjuvant GEM versus mFOLFIRINOX. External validation was performed in the randomized PRODIGE-24/CCTG PA6 trial (n = 313). RESULTS In PRODIGE-24/CCTG PA6, the treatment-specific histology scores used to construct PANCprAId stratified outcomes among patients treated with GEM (hazard ratio [HR], 1.69 [95% CI, 1.04 to 2.73]; P = .03) and mFOLFIRINOX (HR, 2.02 [95% CI, 1.4 to 3.0]; P < .001). When combined into PANCprAId, the biomarker identified subgroups with differential relative benefit from adjuvant GEM versus mFOLFIRINOX, with significant treatment interactions for DFS (interaction P = .003) and cancer-specific survival (interaction P = .001). Predicted sensitivity to each regimen was associated with distinct epithelial and stromal features. CONCLUSION Histology-based deep learning can derive a predictive biomarker of relative benefit from adjuvant GEM versus mFOLFIRINOX in resected PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalDeep LearningHumansChemotherapy, AdjuvantDeoxycytidineRetrospective StudiesFemaleGemcitabineLeucovorinFluorouracilOxaliplatinIrinotecanMalePancreatectomyMiddle AgedAgedBiomarkers, TumorDisease-Free Survival

Substanzen

DeoxycytidineGemcitabineLeucovorinFluorouracilOxaliplatinfolfirinoxIrinotecanBiomarkers, Tumor

Autor:innen und Institutionen

  • Centre de Recherche sur l'Inflammation (CRI), Université Paris Cité, INSERM, U1149, CNRS, ERL 8252, Paris, France.
  • Else Kroener Fresenius Center for Digital Health, Medical Faculty Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
  • Department of Pathology-FHU MOSAIC, Beaujon Hospital, Université Paris Cité, INSERM UMR1149, Clichy, France.
  • Cancer Research Center of Marseille (CRCM), INSERM, CNRS, Institute Paoli-Calmettes, Aix-Marseille University, Marseille, France.
  • Programa franco-argentino de estudio del Cáncer de Páncreas, Buenos Aires, Argentina.
  • Faculty of Medicine, Center for Pharmacological and Botanical Studies, Buenos Aires University, National Council for Scientific and Technical Research, Buenos Aires, Argentina.

ORCID-Profile: Audrey Beaufils, Julien De Martino, Théau Blanchard, Diana Mendes, Camille Pignolet, Taib Bourega, Asier Rabasco Meneghetti, Srividhya Sainath, Miguel Albuquerque, Nathalie Colnot, Matthieu Tihy, Meher Ben Abdelghani, Alice Wei, Emmanuel Mitry, Thierry Lecomte, James Biagi, Pascal Artru, Ludovic Evesque, Aurélien Lambert, Nelson J Dusetti, Thierry Conroy, Jean-Baptiste Bachet, Louis de Mestier, Jérôme Cros, Rémy Nicolle

Förderung

  • NCI NIH HHS

Zitieren

APA

Beaufils, A., De Martino, J., Jiang, X., Blanchard, T., Fraunhoffer, N., Mendes, D., Pignolet, C., Bourega, T., Meneghetti, A. R., Sainath, S., Albuquerque, M., Colnot, N., Tihy, M., Turpin, A., Ben Abdelghani, M., Wei, A., Mitry, E., Lecomte, T., Biagi, J., …, & Nicolle, R. (2026). Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00327

Vancouver

Beaufils A, De Martino J, Jiang X, Blanchard T, Fraunhoffer N, Mendes D, et al. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-00327

BibTeX
@article{Beaufils2026,
  author = {Beaufils, Audrey and De Martino, Julien and Jiang, Xiaofeng and Blanchard, Théau and Fraunhoffer, Nicolas and Mendes, Diana and Pignolet, Camille and Bourega, Taib and Meneghetti, Asier Rabasco and Sainath, Srividhya and Albuquerque, Miguel and Colnot, Nathalie and Tihy, Matthieu and Turpin, Anthony and Ben Abdelghani, Meher and Wei, Alice and Mitry, Emmanuel and Lecomte, Thierry and Biagi, James and Artru, Pascal and Evesque, Ludovic and Lambert, Aurélien and Renouf, Daniel J and Mauduit, Marjorie and Dusetti, Nelson J and Hammel, Pascal and Conroy, Thierry and Bachet, Jean-Baptiste and de Mestier, Louis and Rebours, Vinciane and Cros, Jérôme and Kather, Jakob Nikolas and Nicolle, Rémy},
  title = {Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-26-00327}
}
Kostenlos starten →